Webcast argenx Corporate Presentation - UBS Conference NY - May 22 2018, 2:00 PM EST


ARGX-110 is a first-in-class SIMPLE Antibody™ which potently blocks CD70 activity. There is a significant unmet need in  patients with severe autoimmune diseases who are refractory to current therapies where treatment side-effects remain high (source: Walsh, 2012). Specifically, depleting the small subset of CD70 positive B- and T-cells with minimal impact on the overall B- and T-cell compartments constitutes a rationalized therapeutic goal, potentially associated with a safety advantage.